{
  "pmcid": "4463030",
  "sha256": "f71d4c990dbd5f3e01a8a305c7e3ad0be9684b9465f52556335fac381771c437",
  "timestamp_utc": "2025-11-09T22:42:32.875505+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.364201228878652,
    "reading_ease": 20.72027009728623,
    "word_count": 217
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of ABThera vs. Barker's Vacuum Pack in Reducing Systemic Inflammation"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "single-center, parallel-group randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Forty-five adults undergoing abbreviated laparotomy were randomised"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to ABThera (n=23) or Barker's vacuum pack (n=22)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine if the ABThera temporary abdominal closure device reduces systemic inflammation compared to Barker's vacuum pack."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the difference in plasma IL-6 concentration at 24 and 48 hours post-application."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment via a dedicated website."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Forty-five adults undergoing abbreviated laparotomy were randomised 1:1 to ABThera (n=23) or Barker's vacuum pack (n=22) between September 29, 2011, and December 9, 2012."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "No significant differences were observed in adverse events, including enterocutaneous fistula formation and intra-abdominal hypertension."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 90-day mortality was lower in the ABThera group (HR 0.32, 95% CI 0.11â€“0.93, p=0.04)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant differences were observed in adverse events, including enterocutaneous fistula formation and intra-abdominal hypertension."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ClinicalTrials.gov NCT01355094."
      },
      "Funding": {
        "score": 1,
        "evidence": "The trial was funded by institutional grants."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}